A Phase 1 dose escalating study of ACE-041, a novel inhibitor of ALK-1 mediated angiogenesis, in patients with advanced solid tumors

作者:Sharma S; Bendell J C; Hurwitz H; Condon C H; Thornell B J; Slatcher P L; Borgstein N G; Sherman M L; Gordon M S
来源:22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, 2010-11-16 to 2010-11-19.
DOI:10.1016/S1359-6349(10)72172-8
  • 出版日期2010-11

全文